LENZ Therapeutics (LENZ) Net Income towards Common Stockholders (QoQ) (2020 - 2026)
LENZ Therapeutics (LENZ) Net Income towards Common Stockholders (QoQ) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | LENZ Therapeutics | 177.61 Mn | -80.77 Mn | 825,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.58% |
| Dec 31, 2025 | -114.95% |
| Sep 30, 2025 | -11.99% |
| Jun 30, 2025 | 6.26% |
| Mar 31, 2025 | -25.73% |
| Dec 31, 2024 | -23.86% |
| Sep 30, 2024 | 0.38% |
| Jun 30, 2024 | 36.45% |
| Mar 31, 2024 | 11.23% |
| Dec 31, 2023 | 65.85% |
| Sep 30, 2023 | -6.92% |
| Jun 30, 2023 | -185.59% |
| Mar 31, 2023 | 38.50% |
| Dec 31, 2022 | 17.20% |
| Sep 30, 2022 | 94.62% |
| Jun 30, 2022 | -2,207.31% |
| Mar 31, 2022 | -31.70% |
| Dec 31, 2021 | 61.91% |
| Sep 30, 2021 | 57.87% |
| Jun 30, 2021 | -1,293.34% |